1194054-62-0

Basic information

• Product Name: 2-tert-butyl-5-{4-[2-(2-(tert-butyldimethylsiloxy)ethoxy)ethoxy]benzyloxy}-4-chloro-2H-pyridazin-3-one
• Synonyms: 2-tert-butyl-5-{4-[2-(2-(tert-butyldimethylsiloxy)ethoxy)ethoxy]benzyloxy}-4-chloro-2H-pyridazin-3-one
• CAS NO: 1194054-62-0
• Molecular Weight: 511.134
• Mol File: 1194054-62-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-tert-butyl-5-{4-[2-(2-(tert-butyldimethylsiloxy)ethoxy)ethoxy]benzyloxy}-4-chloro-2H-pyridazin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-tert-butyl-5-{4-[2-(2-(tert-butyldimethylsiloxy)ethoxy)ethoxy]benzyloxy}-4-chloro-2H-pyridazin-3-one(1194054-62-0)
• EPA Substance Registry System: 2-tert-butyl-5-{4-[2-(2-(tert-butyldimethylsiloxy)ethoxy)ethoxy]benzyloxy}-4-chloro-2H-pyridazin-3-one(1194054-62-0)

Safety Data

• Hazardous Substances Data: 1194054-62-0(Hazardous Substances Data)

Upstream product

• 1194054-59-5 4-[2-(2-(tert-butyldimethylsiloxy)ethoxy)ethoxy]phenylmethanol 
• 84956-71-8 2-tert-butyl-4,5-dichloro-2H-pyridazin-3-one 

Downstream Products

• 1194054-65-3 2-(tert-butyl)-4-chloro-5-((4-(2-(2-hydroxyethoxyl)ethoxy)benzyl)oxy)pyridazin-3(2H)-one 

Relevant articles and documents

Preparation and biodistribution of [18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography

Myocardial extractions of pyridaben, a mitochondrial complex I (MC-I) inhibitor, is well correlated with blood flow. Based on the synthesis and characterization of pyridaben analogue 2-tert-butyl-5-[2-(2-[18F]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([18F]FP2OP), this study assessed its potential to be developed as myocardial perfusion imaging (MPI) agent. Methods: The tosylate labeling precursor 2-(2-(4-(tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)benzyloxy)ethoxy)ethyl ester (OTs-P2OP) and the nonradioactive 2-tert-butyl-5-[2-(2-[19F]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([19F]FP2OP) were synthesized and characterized by IR, 1H NMR, 13C NMR and MS analysis. By substituting tosyl of precursor OTs-P2OP with 18F, the radiolabeled complex [18F]FP2OP was prepared and further evaluated for its in vitro physicochemical properties, in vivo biodistribution, the metabolic stability in mice, ex vivo autoradiography and cardiac PET/CT imaging. Results: Starting with [18F]F- Kryptofix 2.2.2./K2CO3 solution, the total reaction time for [18F]FP2OP was about 100 min, with final high-performance liquid chromatography purification included. Typical decay-corrected radiochemical yield stayed at 41 ± 5.3%, the radiochemical purity, 98% or more. Biodistribution in mice showed that the heart uptake of [18F]FP2OP was 41.90 ± 4.52%ID/g at 2 min post-injection time, when the ratio of heart/liver, heart/lung and heart/blood reached 6.83, 9.49 and 35.74, respectively. Lipophilic molecule was further produced by metabolized [18F]FP2OP in blood and urine at 30 min. Ex vivo autoradiography demonstrates that [18F]FP2OP may have high affinity with MC-I and that can be blocked by [19F]FP2OP or rotenone (a known MC-I inhibitor). Cardiac PET images were obtained in a Chinese mini-swine at 5, 15, 30 and 60 min post-injection time with high quality. Conclusion: [18F]FP2OP was synthesized with high radiochemical yield. The promising biological properties of [18F]FP2OP suggest high potential as MPI agent for positron emission tomography in the future.